Dyne Therapeutics slides after J.P. Morgan downgrade tied to Novartis setback
Dyne Therapeutics (DYN) traded lower in premarket after J.P. Morgan downgraded the neuromuscular disease company, citing a study setback affecting a Novartis (NVS) medicine and share pressure in the prior session.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.